Literature DB >> 27904028

Prognostic Value of Eosinophil to Leukocyte Ratio in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Takao Konishi1,2, Naohiro Funayama1, Tadashi Yamamoto1, Toru Morita1, Daisuke Hotta1, Hiroshi Nishihara2, Shinya Tanaka2.   

Abstract

AIM: Leukocyte profile has been related to clinical outcome in patients with ST-segment elevation (STE) myocardial infarction (MI). However, whether eosinophil to leukocyte ratio (ELR) predicts clinical outcome in patients who have undergone primary percutaneous coronary intervention (PCI) remains unclear. Therefore, we examined the prognostic value of ELR in this patient population.
METHODS: We retrospectively analyzed the data of 331 consecutive patients who underwent primary PCI for STEMI between January 2009 and March 2015. All leukocyte types were counted and ELR was calculated for all patients 24 h after hospital admission. The primary study endpoint was major adverse cardiac events (MACEs) within up to one year of follow-up duration.
RESULTS: MACEs including cardiac deaths in 9.4% of the patients, MI in 1.5%, and target lesion or vessel revascularization in 10.3%, occurred within one year in 68 patients (20.5%). The mean ELR was significantly lower in patients with MACEs than in patients without MACEs (0.20±0.51 vs.0.49±0.66, respectively; p<0.001). An ELR <0.1 at 24 h was identified as the best cut-off value for mortality prediction. Multivariate analysis identified that an ELR <0.1 (odds ratio [OR]=0.38; 95% confidence interval [CI]=0.22-0.67; p<0.001) and chronic kidney disease (OR=2.38; CI=1.33-4.24; p=0.003) are independent predictors of MACEs.
CONCLUSION: In primary PCI patients with STEMI, ELR at 24 h was an independent predictor of MACEs in addition to the usual coronary risk factors and commonly used biomarkers.

Entities:  

Keywords:  Eosinophil to leukocyte ratio; Major adverse cardiac event; Percutaneous coronary intervention; ST-segment elevation myocardial infarction

Mesh:

Substances:

Year:  2016        PMID: 27904028      PMCID: PMC5556190          DOI: 10.5551/jat.37937

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  53 in total

1.  Which white blood cell subtypes predict increased cardiovascular risk?

Authors:  Benjamin D Horne; Jeffrey L Anderson; Jerry M John; Aaron Weaver; Tami L Bair; Kurt R Jensen; Dale G Renlund; Joseph B Muhlestein
Journal:  J Am Coll Cardiol       Date:  2005-04-25       Impact factor: 24.094

2.  Plasma cortisol and prognosis of patients with acute myocardial infarction.

Authors:  Sandeep K Jutla; Matthew F Yuyun; Paulene A Quinn; Leong L Ng
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2014-01       Impact factor: 2.160

Review 3.  The effects of glucocorticoids on human eosinophils.

Authors:  R P Schleimer; B S Bochner
Journal:  J Allergy Clin Immunol       Date:  1994-12       Impact factor: 10.793

4.  Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Jin Joo Park; Ho-Joon Jang; Il-Young Oh; Chang-Hwan Yoon; Jung-Won Suh; Young-Seok Cho; Tae-Jin Youn; Goo-Yeong Cho; In-Ho Chae; Dong-Ju Choi
Journal:  Am J Cardiol       Date:  2012-12-27       Impact factor: 2.778

5.  Isolation and partial characterization of human eosinophil granules. Comparison to neutrophils.

Authors:  B C West; N A Gelb; A S Rosenthal
Journal:  Am J Pathol       Date:  1975-12       Impact factor: 4.307

6.  Eosinophil survival and apoptosis in health and disease.

Authors:  Yong Mean Park; Bruce S Bochner
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

7.  Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease.

Authors:  A Slungaard; G M Vercellotti; T Tran; G J Gleich; N S Key
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.

Authors:  Amir Halkin; Gregg W Stone; Cindy L Grines; David A Cox; Barry D Rutherford; Paolo Esente; Carol M Meils; Per Albertsson; Anthony Farah; James E Tcheng; Alexandra J Lansky; Roxana Mehran
Journal:  J Am Coll Cardiol       Date:  2006-02-10       Impact factor: 24.094

9.  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors:  M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

10.  Incidence and Expression of Circulating Cell Free p53-Related Genes in Acute Myocardial Infarction Patients.

Authors:  David Pereg; Keren Cohen; Morris Mosseri; Tatiana Berlin; David M Steinberg; Martin Ellis; Osnat Ashur-Fabian
Journal:  J Atheroscler Thromb       Date:  2015-05-11       Impact factor: 4.928

View more
  9 in total

1.  Association of eosinophil-to-monocyte ratio with 1-month and long-term all-cause mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Xin Deng; Xiaoyan Wang; Li Shen; Kang Yao; Lei Ge; Jianying Ma; Feng Zhang; Juying Qian; Junbo Ge
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Prognostic Value of Circulating Inflammatory Cells in Patients with Stable and Acute Coronary Artery Disease.

Authors:  John A L Meeuwsen; Marian Wesseling; Imo E Hoefer; Saskia C A de Jager
Journal:  Front Cardiovasc Med       Date:  2017-07-14

Review 3.  Regulation of Type 2 Immunity in Myocardial Infarction.

Authors:  Jun-Yan Xu; Yu-Yan Xiong; Xiao-Tong Lu; Yue-Jin Yang
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

4.  Combination of eosinophil percentage and high-sensitivity C-reactive protein predicts in-hospital major adverse cardiac events in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

Authors:  Liu Ye; Hong-Mei Bai; Dan Jiang; Bing He; Xue-Song Wen; Ping Ge; Dong-Ying Zhang
Journal:  J Clin Lab Anal       Date:  2020-05-22       Impact factor: 2.352

Review 5.  Leukocyte-Mediated Cardiac Repair after Myocardial Infarction in Non-Regenerative vs. Regenerative Systems.

Authors:  Elizabeth Anne Peterson; Jisheng Sun; Jinhu Wang
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-21

6.  Hematological Parameter as Predictor Mortality in Acute Myocardial Infarction Patients.

Authors:  Novi Khila Firani; Khoirunisah Dwi Hartanti; Putri Purnamasari
Journal:  Int J Gen Med       Date:  2022-08-23

7.  Eosinophils Protect Mice From Angiotensin-II Perfusion-Induced Abdominal Aortic Aneurysm.

Authors:  Cong-Lin Liu; Xin Liu; Yuanyuan Zhang; Jing Liu; Chongzhe Yang; Songyuan Luo; Tianxiao Liu; Yunzhe Wang; Jes S Lindholt; Axel Diederichsen; Lars M Rasmussen; Marie Dahl; Galina K Sukhova; Guanyi Lu; Gilbert R Upchurch; Peter Libby; Junli Guo; Jinying Zhang; Guo-Ping Shi
Journal:  Circ Res       Date:  2020-11-06       Impact factor: 17.367

8.  Eosinophil Deficiency Promotes Aberrant Repair and Adverse Remodeling Following Acute Myocardial Infarction.

Authors:  Iqbal S Toor; Dominik Rückerl; Iris Mair; Rob Ainsworth; Marco Meloni; Ana-Mishel Spiroski; Cecile Benezech; Jennifer M Felton; Adrian Thomson; Andrea Caporali; Thomas Keeble; Kare H Tang; Adriano G Rossi; David E Newby; Judith E Allen; Gillian A Gray
Journal:  JACC Basic Transl Sci       Date:  2020-07-08

9.  Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion.

Authors:  Cesar Rios-Navarro; Jose Gavara; Veronica Vidal; Clara Bonanad; Paolo Racugno; Antoni Bayes-Genis; Gema Miñana; Oliver Husser; Ricardo Oltra; Julio Nuñez; Francisco J Chorro; Vicente Bodi; Amparo Ruiz-Sauri
Journal:  PLoS One       Date:  2018-10-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.